A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Melphalan; Rituximab
- Indications Multiple myeloma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 10 Feb 2017 Status changed from completed to discontinued.
- 20 Dec 2016 Status changed from discontinued to completed.
- 07 Sep 2016 Status changed from completed to discontinued.